Radiopharmaceuticals: Global Clinical Trial Landscape (2024)

Established originally from radiation therapy, radiopharmaceuticals have made significant development progress in recent years. In 2018, the FDA approved Lutathera for neuroendocrine tumors, signifying a new hope in the treatment of solid tumors. As the global clinical trial landscape continues to evolve, this white paper explores:

Evolution and key focus areas
Market landscape and investment trends
Alpha vs. beta emitters
Global collaboration and approval processes
Growth drivers and future outlook

Download the Whitepaper

Your company email address

Please select your industry: (max 1)
Would you like to hear more from a Novotech expert about clinical trials?

Opt In?

Berne Media may store and process my information. For details, see the Privacy Notice.
Citeline (previously Pharma Intelligence UK) may contact me with updates, relevant promotions and information about products. My Information will be used in accordance with the Citeline Privacy Policy, and you withdraw your permission to receive any of our communications at any time.
By clicking submit, you consent to allow Novotech to store and process the information submitted to provide you the content requested. They are subject to Novotech’s Terms and Conditions.

Radiopharmaceuticals: Global Clinical Trial Landscape (2024)

Download the Whitepaper

Opt In?

Explore similar content

Safety & Regulatory Compliance Predictions For 2025

Maximizing value across drug development: Embracing a new CDMO and CRO partnership approach

Getting The Most Out Of Your Lab Space